Impact of thrombus aspiration use for the treatment of stent thrombosis on early patient outcomes

BACKGROUND: Recent data suggest a clinical benefit with the systematic use of thrombus aspiration (TA) for the treatment of STelevation myocardial infarction (STEMI). Nevertheless, the impact of TA as a treatment strategy for stent thrombosis (ST) is unknown. This study aimed to analyze the impact of TA use for the treatment of ST on patient outcomes. METHODS: From 2003 to 2008, 91 consecutive patients who presented with a definite ST were included in this analysis. We compared procedural success rates and the incidence of the composite criteria deathrecurrent MI-recurrent ST at 30 days in patients who were treated with TA (TA group, n ≤ 36) versus those who were not (No-TA group, n ≤ 55). RESULTS: Baseline characteristics were similar between the two groups except for the body mass index: 26.2 ± 5.4 vs. 29.3 ± 6.2 in the TA and No- TA groups, respectively (p ≤ 0.028). ST presented more likely as STEMI in the TA group: 86.1 vs. 67.3 (p ≤ 0.043). Except for TA use, there was no difference in the treatment therapeutics between groups, including for glycoprotein IIb/IIIa inhibitors. The rate of procedural success was higher in the TA group than in the No-TA group: 88.9 vs. 70.9 (p ≤ 0.043). The incidence of the endpoint of death-recurrent MI-recurrent ST was significantly lower in the TA group: 22.2 vs. 47.2 (p ≤ 0.026). By multivariate analysis, TA use was independently associated with a decrease in the composite criteria (HR ≤ 0.45, p ≤ 0.039). CONCLUSION: This study suggests that TA use for ST treatment permits an improvement in patient outcomes at 30 days with a significant decrease in the incidence of the composite criteria death-recurrent MI-recurrent ST. Further prospective studies are needed, however, to definitively address the benefit of TA use in this particular setting.